Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 7/20 | 0.34 |
| ▸ | XIAP | P98170 | 5/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821016 | 1.00 | GRM2 (0.36) | GRM2PTPN11MLNRXIAPBIRC2 | |
| SCHEMBL5806830 | 1.00 | GRM2 (0.36) | GRM2PTPN11MLNRXIAPBIRC2 | |
| Trifluoroacetic Acid SCHEMBL5955061 | 0.95 | GRM2 (0.34) | GRM2PTPN11MLNRXIAPBIRC2 | |
| Trifluoroacetic Acid SCHEMBL5819784 | 0.95 | GRM2 (0.34) | GRM2PTPN11MLNRXIAPBIRC2 | |
| SCHEMBL5806834 | 0.85 | MLNR (0.37) | GRM2MLNRXIAPBIRC2CHRM3 | |
| SCHEMBL5807018 | 0.82 | HTR6 (0.39) | MLNRXIAPBIRC2 | |
| SCHEMBL5803553 | 0.82 | HTR6 (0.39) | MLNRXIAPBIRC2 | |
| SCHEMBL5823362 | 0.82 | HTR6 (0.39) | MLNRXIAPBIRC2 | |
| SCHEMBL5955903 | 0.81 | MLNR (0.36) | GRM2PTPN11MLNRXIAPBIRC2 | |
| Trifluoroacetic Acid SCHEMBL5820047 | 0.80 | HTR6 (0.35) | MLNRXIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | claimed |
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142269-A1 | New compounds | GPR119, GLP1R, IAPP | GRM2 220/4885PTPN11 2568/4885MLNR 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.